Castle Biosciences (CSTL) revenue breakdown
By product, Dermatologic is the largest at 63% of fiscal 2025 revenue; Non Dermatologic grew fastest, 91% a year over 5 years.
Revenue by product
Fiscal years, as Castle Biosciences reports them in its 10-K filings; fiscal 2025 total $344M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Dermatologic | $58M | $86M | $125M | $183M | $257M | $216M | 63% |
| Non Dermatologic | $5M | $8M | $12M | $36M | $75M | $128M | 37% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CSTL.
Open CSTL in InvestinglyQuestions
Where does Castle Biosciences make its money?
In fiscal 2025, by product: Dermatologic $216M, Non Dermatologic $128M.
From Castle Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.